K
Karyopharm Therapeutics Inc. (KPTI)
NMS – Real Time Price. Currency in USD
10.21
+0.75 (7.93%)
At close: Jun 26, 2026, 4:00 PM EDT
10.18
-0.03 (-0.29%)
After-hours: Jun 26, 2026, 7:42 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
10.21
+0.75 (7.93%)
At close: Jun 26, 2026, 4:00 PM EDT
10.18
-0.03 (-0.29%)
After-hours: Jun 26, 2026, 7:42 PM EDT
No Data
There are no news for this stock.
Total debt $230.9M significantly exceeds cash reserves ($90.8M), raising financial stability concerns
Total current assets $126.3M exceed Total current liabilities $117.3M, highlighting excellent liquidity
Debt-to-equity ratio (-0.9) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-2.1x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$22.7M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.08 | 6.05 | 7.0 | |
| Quick ratio | 1.05 | 5.63 | 7.0 | |
| Debt to Equity | N/A | 0.30 | 1.0 | |
| Debt to Assets | 1.76 | 1.04 | 1.0 | |
| Interest coverage | -2.13 | -16.91 | 1.0 | |
| Weighted average score | 3.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 157M | 146M | 145M | 146M | 151M |
| Gross Profit | 151M | 141M | 139M | 140M | 145M |
| Operating Income | -142M | -130M | -119M | -91M | -84M |
| Net Income | -165M | -143M | -76M | -196M | -195M |
| EBITDA | -142M | -129M | -119M | -90M | -84M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -12.68 | 69.68 | 5.5 |
| Next quarter | -23.16 | 75.06 | 5.5 |
| Current year | -6.06 | 77.24 | 5.5 |
| Next year | 13.18 | 23.53 | 9.0 |
| Weighted average score | 6.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 2.9 | 78.09 | 78.28 | -92.14 | 6.3 |
| Y/Y | 16.83 | 4.56 | 55.23 | 41.7 | 8.3 |
| 3y average | -2.32 | -32.15 | 11.73 | 13.79 | 4.3 |
| 5y average | 12.4 | -18.57 | 10.43 | 7 | 5.0 |
| Weighted average score | 6.0 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |